Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganetespib with Paclitaxel for Triple-Negative Breast Cancer
NCT02637375Withdrawn
- Sponsor
- University of Chicago
- Start
- May 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of ganetespib in triple-negative breast cancer (TNBC), sponsored by University of Chicago. Primary endpoint: Change in Glucocorticoid Receptor protein expression at 2 weeks. Planned start May 2016; status: withdrawn.
02
Drugs
ganetespib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02637375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02637375.